Martin Rohrbach

Martin Rohrbach

Partner, Life Sciences

Das neue Heilmittelgesetz: Fluch oder Segen?

Das neue Heilmittelgesetz wurde zwar bereits vor 2 Jahren verabschiedet, in Kraft tritt es jedoch vermutlich erst am 1. Januar 2019, nach Abschluss des umfangreichen Vernehmlassungsverfahrens. Ziel und Zweck des Gesetzes ist die Regelung der Zulassung und des Vertriebs von Arzneien.
2

EU Medical Device Regulation: What’s the impact?

Following various incidents in recent years, the control mechanisms for medical devices are being tightened throughout Europe with the new EU Medical Device Regulation (MDR) and In Vitro Diagnostics Regulation (IVDR). What is the impact of these EU regulations for Switzerland and how do you ensure compliance on your end by the time the transition period ends?
4

Digitalization reshuffles the deck in life sciences industry

Life science companies will need an integrated digital data strategy with internal and external processes to stay successful and to make use of the available data. At the center of the new life sciency ecosystem is the patient centric view.
2

The decline of the traditional pharmaceutical business model

As the sector stands at a crossroads, the traditional pharmaceutical business model may become obsolete. Although it may be too late to halt its decline, it’s certainly not too late to rethink how pharmaceuticals can adapt and thrive in the face of shifting payer attitudes and patient empowerment.
8 1

Value-based pricing in pharmaceuticals: Hype or Hope?

In the face of stagnant healthcare budgets and ever-growing demand for care, pharmaceutical companies are under severe pressure to demonstrate the value of their products. Value-based pricing has exciting potential to help improve patient outcomes – and at an affordable cost.
10